IMPORTANT SAFETY INFORMATION AND INDICATION
IMPORTANT SAFETY INFORMATION AND INDICATION
RELPAX® (eletriptan HBr) is contraindicated for patients with:
- History of coronary artery disease (CAD) or coronary artery vasospasm
- Wolff-Parkinson-White syndrome or other cardiac accessory conduction pathway disorders
- History of stroke, transient ischemic attack, or history or current evidence of hemiplegic or basilar migraine
- Peripheral vascular disease
- Ischemic bowel disease
- Uncontrolled hypertension
- Within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing medication
- Hypersensitivity to RELPAX (angioedema and anaphylaxis seen)
- Within at least 72 hours of treatment with the following potent CYP3A4 inhibitors: ketoconazole, itraconazole, nefazodone, troleandomycin, clarithromycin, ritonavir, or nelfinavir
RELPAX may cause the following:
- Myocardial ischemia/infarction, Prinzmetal’s angina. These events may occur even in patients without known disease. Perform cardiac evaluation in triptan-naïve patients with multiple risk factors and, if satisfactory, administer first dose of RELPAX in a medically supervised setting.
- Arrhythmias: discontinue RELPAX if these disturbances occur.
- Sensations of chest/throat/neck/jaw pain, tightness, pressure, or heaviness commonly occur after treatment with RELPAX and are usually non-cardiac in origin. Perform a cardiac evaluation if these patients are at cardiac risk.
- Cerebrovascular events, some fatal; non-coronary vasospastic reactions such as gastrointestinal vascular ischemia and Raynaud’s syndrome; and increases in blood pressure have been reported with RELPAX. Discontinue the use of RELPAX if any of these events occur.
- Overuse of acute migraine drugs may lead to exacerbation headache (medication overuse headache). Detoxification of patients, including withdrawal of the overused drugs, and treatment of withdrawal symptoms may be necessary.
- Serotonin syndrome may occur with RELPAX particularly during co-administration with selective serotonin reuptake inhibitors (SSRIs), serotonin norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), and monoamine oxidase inhibitors (MAOIs). The onset of symptoms usually occurs within minutes to hours of receiving a new or greater dose of a serotonergic medication. Discontinue RELPAX if serotonin syndrome is suspected.
In clinical trials, the most common adverse events reported with treatment with RELPAX 40 mg compared with placebo were dizziness (6% vs 3%), somnolence (6% vs 4%), asthenia (5% vs 3%), and nausea (5% vs 5%).
RELPAX should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
RELPAX is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura. RELPAX should be used only after a clear diagnosis of migraine has been established. It is not recommended for the prophylactic treatment of migraine or for the treatment of cluster headache.
Terms and Conditions
By using the RELPAX $4 Savings Offer, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
- This Savings Offer is not valid for prescriptions that are eligible to be reimbursed, in whole or in part, by Medicaid, Medicare, Tricare, or other federal or state healthcare programs (including any state prescription drug assistance programs) and the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma De Salud”)
- You must deduct the savings received under this program from any reimbursement request submitted to your insurance plan, either directly by you or on your behalf
- Eligible patients may pay as little as $4 per monthly prescription. Savings provided by each Savings Offer is limited to $150 per month. Each Savings Offer may be used once per month for twelve (12) months. Provided you continue to meet the eligibility criteria, you may be eligible to receive a second Savings Offer during the offering
- This Savings Offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plans or other health or pharmacy benefit programs
- The Savings Offer is not valid for Massachusetts residents whose prescriptions are covered, in whole or in part, by third-party insurance
- This Savings Offer is not valid where prohibited by law
- The Savings Offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
- The Savings Offer may not be redeemed more than once per month per patient
- The Savings Offer will be accepted only at participating pharmacies
- The Savings Offer is not health insurance
- This Savings Offer is good only in the U.S. and Puerto Rico
- The Savings Offer is limited to 1 per person during this offering period and is not transferable
- Pfizer reserves the right to rescind, revoke, or amend the program without notice
- No membership fees. The Savings Offer and Program expire on 12/31/2020
For help with the RELPAX $4 Savings Offer, call 1-800-926-5334, visit RELPAX.com, or write: Pfizer, ATTN: RELPAX, PO Box 4937, Warren, NJ 07059-6600.
For reimbursement when using a nonparticipating pharmacy/mail order: Pay for your RELPAX prescription and mail copy of original pharmacy receipt (cash register receipt NOT valid) with product name, date, and amount circled to: Pfizer, ATTN: RELPAX, PO Box 4937, Warren, NJ 07059-6600. Be sure to include a copy of the front of your RELPAX Savings Offer, your name, and mailing address. Please expect up to 4 to 6 weeks for reimbursement.
- Sandrini G, Färkkilä M, Burgess G, Forster E, Haughie S, for the Eletriptan Steering Committee. Eletriptan vs sumatriptan: a double-blind, placebo-controlled, multiple migraine attack study. Neurology. 2002;59(8):1210-1217.
- Mathew NT, Schoenen J, Winner P, Muirhead N, Sikes CR. Comparative efficacy of eletriptan 40 mg versus sumatriptan 100 mg. Headache. 2003;43(3):214-222.
Imitrex® (sumatriptan succinate) is a registered trademark of GlaxoSmithKline.